Eikon Therapeutics
Biotechnology company using super-resolution microscopy and AI to discover novel drug targets and develop treatments for cancer and other serious diseases by observing protein dynamics in living cells.
Notes
Eikon Therapeutics is a biotechnology company based in Hayward, California, founded by Nobel laureate Eric Betzig. The company has developed a revolutionary drug discovery platform that combines super-resolution microscopy with artificial intelligence to observe and analyze protein behavior in living cells at unprecedented resolution.
Eikon's technology allows researchers to watch proteins move and interact in real-time within cells, providing insights into biology that were previously impossible to obtain. This approach enables the discovery of novel drug targets and the development of therapeutics for diseases including cancer.
The company has raised substantial funding, including a $350.7 million Series D round in 2025, making it one of the most well-funded private biotech companies.
Team
- Roger Perlmutter, M.D., Ph.D. - CEO (former President of Merck Research Laboratories)
- Eric Betzig, Ph.D. - Founder & Scientific Advisor (Nobel Laureate in Chemistry 2014)
Additional Research Findings
- Founded in 2019
- Raised $350.7 million in Series D (February 2025)
- Total funding over $850 million
- Lead investors: Foresite Capital, Lux Capital, The Column Group
- Founded by Nobel laureate Eric Betzig
- Super-resolution microscopy platform
- AI-powered drug discovery
- Focus on oncology
- Led by former Merck Research Labs head Roger Perlmutter
- Headquarters in Hayward, California
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Foresite Capital | San Francisco, USA | biotech-focused | series-aseries-b+2 | 3 |
| Lux Capital | New York, New York, USA | biotech-focused | seedseries-a+3 | 2 |
| The Column Group | San Francisco, California, USA | biotech-focused | seedseries-a+3 | 1 |